Evidence map›Paper›PMID 19578435›Full record

ArticlePLoS pathogens2009

NOD2, RIP2 and IRF5 play a critical role in the type I interferon response to Mycobacterium tuberculosis.

Amit K Pandey, Yibin Yang, Zhaozhao Jiang, Sarah M Fortune, Francois Coulombe, Marcel A Behr, Katherine A Fitzgerald, Christopher M Sassetti, Michelle A Kelliher

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 158 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
158citing papers in PubMed, 1 pooled it
9.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

158 citing papers in PubMed, 1 synthesis or guideline pooled it, 283 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Gut microbes · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Mutual regulations betweenFrontiers in immunology · 2024
    Review
  18. Review
  19. Microbial cues stimulate linear growth in undernourished mice.Nature reviews. Gastroenterology & hepatology · 2023
    Article
  20. Article

98 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Amit K PandeyDepartment of Molecular Genetics and Microbiology, University of Massachusetts Medical School, Worcester, MA, USA.
Yibin Yang
Zhaozhao Jiang
Sarah M Fortune
Francois Coulombe
Marcel A Behr
Katherine A Fitzgerald
Christopher M Sassetti
Michelle A Kelliher
University of Massachusetts Chan Medical School · USMcGill University Health Centre · CAHarvard University · US

Funding

Rip Proteins in Innate Immune SignalingR01AI075118 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI KELLIHER, MICHELLE ALICE · 2009 to 2024
$6.7M
Tuberculosis Pathogenesis and Drug ResponseR01AI064282 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SASSETTI, CHRISTOPHER M · 2007 to 2017
$3.9M
Regulation of Type I Interferon Gene Expression in the Innate Immune ResponseR01AI067497 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI FITZGERALD, KATHERINE A. · 2006 to 2010
$2.0M
NIAID NIH HHS R01 AI064282NIAID NIH HHS R01 AI067497NIAID NIH HHS R01 AI075118
6 · The paper itself

Abstract

While the recognition of microbial infection often occurs at the cell surface via Toll-like receptors, the cytosol of the cell is also under surveillance for microbial products that breach the cell membrane. An important outcome of cytosolic recognition is the induction of IFNalpha and IFNbeta, which are critical mediators of immunity against both bacteria and viruses. Like many intracellular pathogens, a significant fraction of the transcriptional response to Mycobacterium tuberculosis infection depends on these type I interferons, but the recognition pathways responsible remain elusive. In this work, we demonstrate that intraphagosomal M. tuberculosis stimulates the cytosolic Nod2 pathway that responds to bacterial peptidoglycan, and this event requires membrane damage that is actively inflicted by the bacterium. Unexpectedly, this recognition triggers the expression of type I interferons in a Tbk1- and Irf5-dependent manner. This response is only partially impaired by the loss of Irf3 and therefore, differs fundamentally from those stimulated by bacterial DNA, which depend entirely on this transcription factor. This difference appears to result from the unusual peptidoglycan produced by mycobacteria, which we show is a uniquely potent agonist of the Nod2/Rip2/Irf5 pathway. Thus, the Nod2 system is specialized to recognize bacteria that actively perturb host membranes and is remarkably sensitive to mycobacteria, perhaps reflecting the strong evolutionary pressure exerted by these pathogens on the mammalian immune system.

Indexed as

Acetylmuramyl-Alanyl-IsoglutamineAnimalsBacterial ProteinsCell LineInterferon Regulatory Factor-3Interferon Regulatory FactorsInterferon Type IMacrophagesMiceMice, Inbred C57BLMutationMycobacterium tuberculosisNod2 Signaling Adaptor ProteinProtein Serine-Threonine KinasesReceptor-Interacting Protein Serine-Threonine Kinase 2Receptor-Interacting Protein Serine-Threonine KinasesAcetylmuramyl-Alanyl-IsoglutamineBacterial ProteinsInterferon Regulatory Factor-3Interferon Regulatory FactorsInterferon Type IIrf3 protein, mouseIrf5 protein, mouseNod2 protein, mouseNod2 Signaling Adaptor ProteinProtein Serine-Threonine KinasesReceptor-Interacting Protein Serine-Threonine Kinase 2Receptor-Interacting Protein Serine-Threonine KinasesRipk2 protein, mouseTbk1 protein, mouseUbiquitin

Identifiers

PMID19578435
PMCPMC2698121
OpenAlexW2158342892

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.